Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN studySilvia Nozza, Adriano Lazzarin, Francesco Mazzotta et al.|Clinical Microbiology and Infection|2014Cited by 26
Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trialMarco Ripa, Giuseppe Tambussi, Manuela Pogliaghi et al.|Clinical Microbiology and Infection|2015Cited by 14